Isentress Gets Unanimous Nod From Advisory Committee, But May Get Limited Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Discussion of the indication for Merck’s raltegravir centered on whether the HIV therapy should be approved only for the highly treatment-experienced population studied in clinical trials.
You may also be interested in...
Isentress Approval Carries Limited Indication
FDA follows lead of its September Antiviral Drugs Advisory Committee recommendation.
Isentress Approval Carries Limited Indication
FDA follows lead of its September Antiviral Drugs Advisory Committee recommendation.
FDA Review Of Merck’s Novel HIV Drug Isentress Shows No Clear Efficacy Or Safety Concerns
FDA is asking its Antiviral Drugs Advisory Committee at the Sept. 5 meeting to consider HIV general treatment issues and postmarketing strategies for Merck’s integrase inhibitor, Isentress (raltegravir), which is up for accelerated approval.